Health & Fitness
Thu, May 31, 2012Wed, May 30, 2012Tue, May 29, 2012Mon, May 28, 2012Sun, May 27, 2012Sat, May 26, 2012Fri, May 25, 2012Thu, May 24, 2012Wed, May 23, 2012Tue, May 22, 2012Mon, May 21, 2012Sun, May 20, 2012Sat, May 19, 2012Fri, May 18, 2012Thu, May 17, 2012Questcor Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference
//health-fitness.news-articles.net/content/2012/ .. jefferies-2012-global-healthcare-conference.html
Published in Health and Fitness on Thursday, May 24th 2012 at 9:05 GMT by Market WireQuestcor Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference -- ANAHEIM, Calif., May 24, 2012 /PRNewswire/ --
Questcor Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference
ANAHEIM, Calif., May 24, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: [ QCOR ]) announced today that executive management will present at the Jefferies 2012 Global Healthcare Conference in New York on June 6, 2012 at 5:00 a.m. PT / 8:00 a.m. ET.
A live webcast and subsequent archived replay of the presentation will be accessible at [ http://ir.questcor.com/events.cfm ]. The replay will be available for approximately 90 days after the event.
About Questcor
Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions. Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of proteinuria in idiopathic types of nephrotic syndrome, the treatment of acute exacerbations of multiple sclerosis in adults, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor is also currently preparing to launch a pilot effort in rheumatology, as Acthar is approved for several rheumatology-related conditions including Lupus, Dermatomyositis, Polymyositis and Rheumatoid Arthritis. Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need. For more information about Questcor, please visit [ www.questcor.com ].
SOURCE Questcor Pharmaceuticals, Inc.
[ Back to top ] RELATED LINKS
[ http://www.questcor.com ]
